Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group

Trial Profile

Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisone (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 19 May 2024 to 19 May 2025.
    • 12 Sep 2017 Planned primary completion date changed from 19 Apr 2020 to 19 May 2020.
    • 12 Sep 2017 Planned initiation date changed from 15 Sep 2017 to 15 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top